Ozempic Under Scrutiny: Weight Loss, Side Effects and the Growing GLP-1 Lawsuits

Written by Editor

Medical and Legal Disclaimer: This article is for general informational and educational purposes only and does not constitute medical or legal advice. Ozempic, Wegovy and other GLP-1 or related medicines are prescription medications and should only be taken following an individual medical assessment and under appropriate clinical supervision. Never start, stop or alter the dosage of a prescribed medication without consulting a qualified healthcare professional. References to lawsuits concern allegations made in ongoing litigation and should not be interpreted as findings of liability, negligence or proof that a particular medicine caused an individual patient’s injury. Regulatory and litigation information is correct to the best of our knowledge as of August 2026.

From Diabetes Treatment to a Global Weight-Loss Phenomenon

Few prescription medicines have attracted as much public attention in recent years as Ozempic. Celebrity discussion, social-media transformations and growing demand for rapid weight reduction have turned the once relatively specialised diabetes treatment into a household name.

However, the popularity of Ozempic as a weight-loss injection can obscure an important fact: Ozempic was developed and authorised primarily as a treatment for type 2 diabetes, not as a general-purpose slimming injection.

Ozempic contains semaglutide, a glucagon-like peptide-1 receptor agonist, more commonly known as a GLP-1 receptor agonist. It imitates the effects of the naturally occurring GLP-1 hormone, helping the body release insulin when glucose levels are elevated, reducing glucagon secretion, slowing stomach emptying and affecting appetite.

The current US prescribing information states that Ozempic is indicated for adults with type 2 diabetes to improve blood-glucose control and also has indications relating to cardiovascular and kidney risks in certain people with type 2 diabetes. It is not labelled by the FDA as an obesity or general weight-loss treatment.

The European Medicines Agency similarly describes Ozempic as a medicine for adults with insufficiently controlled type 2 diabetes. Weight reduction can occur during treatment, but this does not turn Ozempic itself into an authorised cosmetic weight-loss medicine.

Why Does Ozempic Cause Weight Loss?

The weight-loss effect is not accidental. GLP-1 activity can reduce appetite and food intake while slowing the rate at which food leaves the stomach. People may consequently feel fuller sooner and remain satisfied for longer.

Semaglutide is therefore also marketed under the name Wegovy, which is specifically authorised for weight management in qualifying patients. The FDA confirms that Wegovy is approved for long-term weight reduction in adults with obesity, or adults who are overweight and have at least one weight-related medical condition.

The EMA similarly authorises Wegovy for weight management alongside diet and physical activity in appropriate patients. Clinical trials submitted for European authorisation demonstrated substantial average weight reductions in some populations.

This distinction matters. Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are different licensed products, with different approved indications and dosing strategies.

Using Ozempic specifically for weight loss where that use is outside its authorised indication is commonly described as off-label prescribing.

Are All GLP-1 Drugs the Same?

Not quite.

Medicines frequently discussed together include Ozempic, Wegovy and Rybelsus containing semaglutide; Saxenda and Victoza containing liraglutide; Trulicity containing dulaglutide; and several other GLP-1 receptor agonists.

Mounjaro and Zepbound contain tirzepatide, which is slightly different because it acts on both GIP and GLP-1 receptors.

Many of these medicines produce similar gastrointestinal effects because they influence appetite, digestion and gastric emptying. However, it would be inaccurate to say that every drug has exactly the same side effects, contraindications or frequency of complications. Dose, active ingredient, indication, individual medical history and interactions with other medicines all matter.

The EMA itself distinguishes between medicines authorised only for diabetes and those authorised for weight management. It has specifically warned against using these medications for cosmetic weight loss in people who do not have obesity or qualifying weight-related health problems.

Common and Serious Side Effects of Ozempic and Similar Medicines

The following represents important overlapping side effects and safety concerns associated with Ozempic and similar GLP-1 medicines. Not every effect applies equally to every product, and patients should always consult the individual patient-information leaflet.

Nausea: One of the most frequently reported effects. Slower gastric emptying and changes in appetite can make people feel sick, particularly when treatment begins or the dose increases. The FDA lists nausea among Ozempic’s most common adverse reactions.
Vomiting: Some patients experience vomiting, particularly during dose escalation. Repeated vomiting can contribute to dehydration and electrolyte disturbances.
Diarrhoea: Loose or frequent stools are common with GLP-1 medicines and may contribute to dehydration when severe or persistent.
Constipation: Slower gastrointestinal movement can lead to constipation. Post-marketing reports for Ozempic have also included severe constipation and faecal impaction.
Abdominal pain, indigestion, reflux, wind and bloating: Digestive discomfort is common. Ozempic trials have reported abdominal pain, dyspepsia, belching, flatulence, reflux and gastritis.
Gastroparesis and severe gastrointestinal symptoms: GLP-1 medicines slow stomach emptying. The current FDA prescribing information warns that severe gastrointestinal adverse reactions can occur and states that Ozempic is not recommended in patients with severe gastroparesis.
Ileus and intestinal obstruction: Post-marketing reports involving Ozempic have included ileus, intestinal obstruction and severe constipation. A post-marketing report does not by itself prove that the medicine caused an individual event, but these reports form an important part of continuing medicine-safety surveillance.
Pancreatitis: Acute inflammation of the pancreas has been observed in people receiving GLP-1 receptor agonists. Severe and persistent abdominal pain, particularly if it radiates towards the back, requires urgent medical assessment.
Gallstones and gallbladder inflammation: Cholelithiasis and cholecystitis have been reported during clinical trials and after marketing. Significant or rapid weight loss itself can also influence gallstone risk.
Kidney injury associated with dehydration: Severe vomiting, diarrhoea or reduced fluid intake can lead to volume depletion. The FDA has received post-marketing reports of acute kidney injury in semaglutide users, including cases requiring dialysis, with many reports involving preceding gastrointestinal symptoms and dehydration.
Low blood sugar: Hypoglycaemia can occur, particularly when a GLP-1 medicine is combined with insulin or medicines that stimulate insulin secretion such as sulfonylureas. The risk is therefore different for someone taking the medicine alone compared with a patient taking several diabetes treatments.
Diabetic retinopathy complications: Ozempic’s FDA information warns about worsening diabetic retinopathy in some people with diabetes, particularly where retinopathy already exists and blood-glucose control changes rapidly.
NAION and sudden vision loss: In June 2025, the EMA’s Pharmacovigilance Risk Assessment Committee concluded that non-arteritic anterior ischaemic optic neuropathy (NAION) should be considered a very rare side effect of semaglutide medicines, including Ozempic, Wegovy and Rybelsus. EMA estimated the frequency at up to approximately 1 in 10,000 people and said observational evidence suggested roughly one additional NAION case per 10,000 person-years of semaglutide treatment. Patients experiencing sudden or rapidly worsening eyesight should seek urgent medical attention.
Serious allergic reactions: Anaphylaxis and angioedema have been reported and require urgent medical attention.
Possible thyroid C-cell tumour risk: US Ozempic labelling carries a boxed warning because semaglutide caused thyroid C-cell tumours in rodents. Whether semaglutide causes these tumours, including medullary thyroid carcinoma, in humans remains unknown. Ozempic is contraindicated in the US in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Risk during anaesthesia or deep sedation: Because GLP-1 medicines can delay stomach emptying, rare reports have described food or stomach contents entering the lungs during procedures requiring general anaesthesia or deep sedation. Patients should tell surgical and anaesthetic teams that they use a GLP-1 medicine before undergoing a procedure.

These risks demonstrate why GLP-1 medicines should not be viewed as casual beauty or lifestyle products simply because they can produce dramatic weight loss.

The Ozempic Lawsuits

The controversy surrounding Ozempic has increasingly entered the courts.

Thousands of US product-liability cases concerning GLP-1 medicines have been consolidated into federal multidistrict litigation.

MDL No. 3094, being handled in the Eastern District of Pennsylvania, concerns alleged gastrointestinal injuries associated with medicines including Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro. The federal court describes the cases as personal-injury claims involving allegations concerning the medicines’ alleged propensity to cause gastrointestinal injuries.

According to the US Judicial Panel on Multidistrict Litigation’s report dated 3 August 2026, 3,928 actions were pending in MDL 3094, with 3,962 actions historically associated with the litigation.

There is now a separate litigation concerning eyesight.

MDL No. 3163 involves claims alleging that GLP-1 medicines caused NAION, an optic-nerve condition capable of causing permanent vision loss. The court states that these actions include claims involving development, manufacture, testing, regulatory history, promotion and labelling, as well as allegations concerning the drugs’ capacity to cause NAION.

As of 3 August 2026, the Judicial Panel reported 200 pending actions in the NAION MDL.

It is essential to distinguish an allegation from a legal finding. Consolidating cases into an MDL allows courts to deal efficiently with common factual and legal questions. It does not mean that the court has concluded that Ozempic caused every alleged injury or that its manufacturers are legally liable. Those questions must be established through the litigation process.

The Eye-Risk Controversy Is Particularly Significant

The NAION issue demonstrates how medicine-safety information can evolve after a medicine reaches millions of patients.

EMA’s safety committee reviewed clinical trials, epidemiological studies, post-marketing information and other evidence before concluding that NAION is a very rare semaglutide side effect. The EMA has recommended updating semaglutide product information accordingly.

The FDA has separately identified NAION as a potential safety signal involving the GLP-1 receptor agonist class and has stated that it was evaluating the need for regulatory action.

This does not mean everyone using semaglutide is likely to develop eye problems. The absolute risk identified by the EMA remains very small, but sudden loss or rapid deterioration of vision should never be ignored.

What About Reports of Depression and Suicidal Thoughts?

This is another area where evolving scientific evidence is important.

Concerns had previously been raised about suicidal thoughts or behaviour among people taking weight-management medicines. However, following a much larger review, the FDA announced in January 2026 that it had not found an increased risk of suicidal ideation or behaviour associated with GLP-1 receptor agonists.

Its analysis included 91 placebo-controlled trials containing 107,910 patients as well as a large healthcare-data study involving more than two million people. The FDA consequently requested removal of suicidal-behaviour and ideation warnings from the relevant GLP-1 weight-management medicine labelling.

This is an important example of why suspected side effects should not automatically be described as proven side effects. Pharmacovigilance requires regulators to investigate signals and then revise advice according to the totality of evidence.

Are GLP-1 Drugs Safe for Weight Loss?

The most accurate answer is: they can be appropriate and sufficiently safe for weight management in the right patient, using the right medicine, at the right dose and under medical supervision, but they are not risk-free.

Regulators approve medicines when available evidence shows that their expected benefits outweigh their known and reasonably foreseeable risks for a particular group of patients and indication.

The FDA has approved medicines such as Wegovy for chronic weight management in qualifying patients and Zepbound for weight reduction and long-term weight maintenance in adults with obesity or overweight accompanied by certain health conditions.

Likewise, the EMA authorises Wegovy for appropriate weight-management patients and authorises Mounjaro for both diabetes and weight management under defined circumstances.

That is very different from taking Ozempic simply because somebody wants to lose a few kilograms before a holiday, wedding or social event.

The EMA has explicitly stated that GLP-1 receptor agonists should not be used for cosmetic weight loss in people without obesity or in people who are overweight but do not have qualifying weight-related health problems.

The FDA’s Position

The FDA’s position is not that semaglutide is inherently unsafe. Rather, different semaglutide products have been approved for different uses.

Ozempic remains an approved medicine for type 2 diabetes and associated indications, while Wegovy is specifically authorised for weight management in qualifying populations. FDA approval therefore supports the use of semaglutide for weight management when an approved weight-management product is prescribed for an approved indication.

The FDA has nevertheless issued strong warnings about unapproved, compounded, fraudulent and counterfeit GLP-1 products. In June 2026 it reported fraudulent compounded semaglutide and tirzepatide products, dosing errors and adverse events associated with some compounded preparations.

Consumers should consequently be extremely cautious about injections advertised online or on social media as cheap alternatives to authorised Ozempic, Wegovy or Mounjaro products.

The EMA’s Position

The EMA takes a similarly balanced approach.

It recognises that authorised GLP-1 medicines can provide important benefits for diabetes and obesity when used appropriately, while warning that they are prescription medicines requiring medical supervision.

The agency has stated that Ozempic and several other GLP-1 drugs are authorised for diabetes only, while medicines such as Wegovy and Saxenda are specifically authorised for weight management and Mounjaro has both diabetes and weight-management indications in the EU.

The EMA has also warned consumers about illegal GLP-1 medicines advertised through fraudulent websites and social media, noting that such products may contain incorrect ingredients, harmful substances or no genuine active medicine at all.

Prescription Does Not Mean Risk-Free

A common misconception is that if a medicine has regulatory approval, it must be completely safe.

No effective medicine is entirely without risk.

Approval instead means regulators have concluded that, for the authorised patient population and use, the benefit-risk balance is favourable based on available evidence.

That balance can change between individuals.

Someone living with clinically significant obesity and serious weight-related disease may have substantial potential health benefits from medically supervised weight reduction. The same risk may be much harder to justify for a healthy person seeking a rapid cosmetic change.

Healthcare professionals therefore need to consider medical history, other medications, diabetes status, gastrointestinal conditions, gallbladder and pancreatic history, kidney health, eye conditions, pregnancy considerations and other individual factors before prescribing.

Weight-Loss Culture and the Ethical Debate

The Ozempic phenomenon also raises broader ethical questions.

Social media can turn a prescription medicine into a fashion trend, while before-and-after photographs rarely reveal nausea, digestive problems, loss of appetite, medical monitoring or the possibility that treatment may need to continue long-term.

There is also an equity issue. When diabetes medicines are diverted extensively into off-label cosmetic use, patients who require them for established medical conditions may face difficulties obtaining their prescriptions. The EMA has previously identified excessive off-label demand as a factor contributing to supply pressures and urged prescribers to follow authorised indications.

Obesity itself, however, should not be trivialised. It is a chronic disease associated with significant health consequences, and people living with obesity should not be shamed for receiving evidence-based medical treatment.

The distinction should therefore be between clinically appropriate obesity treatment and casual or cosmetic use, not between people who supposedly “deserve” medication and those who do not.

Conclusion

Ozempic has changed the conversation surrounding diabetes, obesity and medical weight management.

Its success has also produced a difficult paradox: a medicine that provides significant benefits to many patients has simultaneously become associated with social-media-driven demand, off-label cosmetic use, counterfeit products, evolving safety concerns and thousands of product-liability claims.

The evidence does not support describing Ozempic or the wider GLP-1 class as universally dangerous. Nor does regulatory approval justify treating these medicines as harmless slimming aids.

Ozempic is principally a diabetes medicine. Semaglutide can legitimately be used for weight management through appropriately authorised products such as Wegovy, and other medicines including Mounjaro or Zepbound have approved weight-management indications depending upon the jurisdiction.

The safest approach remains medical assessment, informed consent, appropriate prescribing, gradual dose titration, continuing monitoring and prompt investigation of concerning symptoms.

As the current gastrointestinal and NAION litigation demonstrates, pharmacovigilance does not stop once a drug reaches the market. Regulators, manufacturers, doctors, researchers and courts will continue examining emerging evidence—and patients should be given enough balanced information to make genuinely informed decisions about both the potential benefits and the potential risks.